Effect of Sinbiotic on faster treatment of neonatal jaundice

The effect of Sinbiotics (Prebiotics and Probiotics) with standard phototherapy on treatment of neonatal hyperbilirubinemia with 2-14 days of age in compare with standard phototherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017041933523N1

Enrollment

Registered

2017-11-19

Start date

2017-02-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Jaundice. Physiological jaundice (intense)(prolonged) NOS

Interventions

Intervention 1: In control group neonates treat with photo therapy in 3 days. Neonates treat with 8 lamps photo therapy systems of Tusan brand using TL 20W/52 lamps with 425-475 Nanometer (nm) wavele

Treatment - Other

Treatment - Drugs

In control group neonates treat with photo therapy in 3 days. Neonates treat with 8 lamps photo therapy systems of Tusan brand using TL 20W/52 lamps with 425-475 Nanometer (nm) wavelength and 20-25

In intervention group in addition to 3 days photo therapy, Sinbiotic (Probiotic and Prerbiotic) like Pedilact oral drop 5 drops each days (equivalent 109 Colony Forming Units (CFU) of Lactobacillus re

Eligibility

Sex/Gender

All

Age

2 Days to 14 Days

Inclusion criteria

Inclusion criteria: Inclusion criteria: Neonates with 2 to 14 days of age; Neonates with serum bilirubin level more than 15 milligrams per deciliter (mg/dl) and direct bilirubin less than 1.5 mg/dl; Neonates with normal retic count; Neonates do not have Cephalohematoma and Caputsuccedaneum; Neonates with more than 37 weeks gestational age; Neonates with more than 2500 grams birth weight; Neonates without Polycythemia (Hematocrit more than 65); Neonates without past medical history; Neonates without blood exchange. Exclusion criteria: Neonates with low Hemoglobin and positive Glucose-6- Phosphate Dehydrogenase (G6PD) and Direct Coombs; Neonates that have Cephalohematoma and Caputsuccedaneum; Neonates that their parents do not have satisfaction; Neonates that receive serum therapy, Antibiotic therapy and Intravenous Immunoglobulin (IVIG) therapy; Neonates that have abnormal Peripheral Blood Smear (PBS).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Level of serum bilirubin. Timepoint: One, 2 and 3 days after treatment. Method of measurement: Milligram per Deciliter with laboratorial study of neonates' blood.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSorur Yari

Sabzevar University of Medical Science

www.soruryari1991@yahoo.com+98 51 4401 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026